Matador's reported earnings and its cash earnings have been separated by a contract with a termination date, and the market has been pricing the former.
Read Article ›The market is now valuing AppLovin below a diversified mega-cap advertising platform on forward earnings while it grows two to three times as fast, generates over 60% net margins, carries essentially no net debt, and retires stock.
Read Article ›At roughly 25x next year's consensus earnings for a business converting three-quarters of net income to cash and taking share on both sides of the Atlantic, Eli Lilly is mispriced to the upside — and the risk-reward has not turned, it has merely become less generous than it wa...
Read Article ›What tips the balance is that the approval was not the whole catalyst — it was the start of a data stream that gets richer, not thinner, from here.
Read Article ›The company is a fixed-fee volume engine that beat on reliability, is forward-sold through year-end, has a funded ramp to 60–63 MTPA nearly complete, and is retiring roughly 3% of its shares a year.
Read Article ›Guidance went up, not down; the contract book lengthened; a landmark acquisition closed and its integration proceeded on plan.
Read Article ›The reason the multiple is compressed is not that anyone doubts the ad engine; it is that Meta, alone among the hyperscalers, has no third-party cloud line absorbing the spend.
Read Article ›The harder, less-discussed truth about BridgeBio is that the equity sitting on top of this franchise is a thin residual behind a capital structure that private-credit and private-equity sponsors engineered to harvest the ramp first.
Read Article ›At ~19x forward earnings on a franchise whose fee rate has inflected up after a decade of compression, with capital return stepping up and the two genuine risks slow-burning and priced into the downside case, BlackRock is worth owning through the volatility — not because it is...
Read Article ›The discount as struck double-counts Argentina — once in the multiple and again in the reflex to distrust cash flows that are demonstrably Brent-linked and demonstrably deleveraging the balance sheet. The tape has earned back at least one of those two discounts.
Read Article ›The risk-reward here is skewed favorably for a specific and unusual reason: the earnings math is more knowable than that of almost any agency, and the market is charging almost nothing for it. The category is structurally challenged and the franchise is thin — those are real, ...
Read Article ›The signed backlog says the consensus deceleration curve is too steep, and while that gap persists the stock can grind higher on upward revisions rather than on further multiple expansion. That is the constructive case, and it is a real one: bookings running ahead of revenue, ...
Read Article ›For years the bear objection to WESCO's data-center growth was structural: hyperscale projects are enormous but competitively bid, and volume that dilutes margin is worth less than the revenue line suggests.
Read Article ›The hinge of the whole situation is a single line in the second-quarter results. Strip it out and clean 2026 earnings power sits closer to $15 a share — and 2027 then benefits a second time, because the refinancing itself lowers the ongoing interest bill.
Read Article ›At roughly 26x forward free cash flow for a contracted AI franchise with a fabless cost structure and a software annuity behind it, Broadcom is worth owning for the compounding, with the clear-eyed understanding that six customers and 95% wafer concentration make the bear case...
Read Article ›The consensus reading is that this is a fully-valued yield vehicle: a solid 6% payer trading at ~11x EBITDA, worth owning for income and little more. My argument is that the operating engine is compounding meaningfully faster than that framing credits, that the loudest bear ob...
Read Article ›The market has taken the world’s most-owned stock and, inside two months, compressed it to roughly 22–24x consensus NTM / FY27 earnings — not clearly below the S&P 500, but strikingly close to a market multiple for a company whose revenue just grew 85% year over year — on a be...
Read Article ›The bull/bear standoff here is well worn — an elite compounding franchise trading at roughly 40x earnings against a structural share issuance overhang. That framing is the starting point, not the answer. What tips the balance is the cadence of the underlying metrics: account, ...
Read Article ›The private-credit fear that cut the stock by nearly 40% is aimed at roughly a twentieth of the platform. At ~15x forward adjusted earnings after a brutal drawdown, the confirmation risk over the next several quarters sits with the bears. This is a high-quality compounder on s...
Read Article ›The standing critique of Rocket Lab is simple: elite growth, elite vision, no profits, and a valuation that requires everything to go right. The Iridium acquisition is the most direct possible response to that critique, because Iridium is the thing Rocket Lab has never had—a c...
Read Article ›